ÌÇÐÄvlog

[Skip to Navigation]
Sign In

October 2024 - April 2015

Decade

Year

Issue

October 2022, Vol 8, No. 10, Pages 1379-1520

Original Investigation

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1411-1418. doi:10.1001/jamaoncol.2022.3511

This randomized clinical trial compares the efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with metastatic clear-cell renal cell carcinoma.

Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG)

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1420-1425. doi:10.1001/jamaoncol.2022.3218

This phase 2 nonrandomized clinical trial examines the association of cabazitaxel treatment for patients with advanced dedifferentiated liposarcoma with progression-free survival.

Assessment of Lung Cancer Risk Among Smokers for Whom Annual Screening Is Not Recommended

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1428-1437. doi:10.1001/jamaoncol.2022.2952

This cohort study of data on participants in the Cardiovascular Health Study assesses risk of lung cancer in smokers for whom low-density computed tomographic screening is not recommended.

Relapse Rates and Disease-Specific Mortality Following Procedures for Fertility Preservation at Time of Breast Cancer Diagnosis

Abstract Full Text
open access
JAMA Oncol. 2022;8(10):1438-1446. doi:10.1001/jamaoncol.2022.3677

This cohort study investigates the risk of disease-specific mortality and relapse in women who underwent fertility preservation with or without hormonal stimulation compared with women who did not at time of breast cancer diagnosis.

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2022;8(10):1447-1455. doi:10.1001/jamaoncol.2022.3395

This randomized clinical trial assesses whether etoposide plus cisplatin or irinotecan plus cisplatin is a more effective treatment regimen in terms of overall survival in patients with advanced neuroendocrine carcinoma of the digestive system.

Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1456-1465. doi:10.1001/jamaoncol.2022.3707

This systematic review and meta-analysis examines the predictive value of tissue-based PD-L1 status compared with other variables for ICI benefit among 17 randomized clinical trials including 11 166 patients with advanced gastroesophageal cancer.

Brief Report

Patterns of Practice and Improvements in Survival Among Patients With Stage 2/3 Rectal Cancer Treated With Trimodality Therapy

Abstract Full Text
open access has audio
JAMA Oncol. 2022;8(10):1466-1470. doi:10.1001/jamaoncol.2022.2831

This cohort study describes changes between 2006 and 2016 in the use of trimodality therapy for patients with stage 2/3 rectal cancer and identifies associations with pathologic stage and survival over time.

Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1471-1476. doi:10.1001/jamaoncol.2022.2970

This cohort study uses US Veterans Health Administration data to assess the association of prostate-specific antigen screening with prostate cancer–specific mortality among non-Hispanic Black men and non-Hispanic White men.

Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19

Abstract Full Text
free access has active quiz
JAMA Oncol. 2022;8(10):1477-1483. doi:10.1001/jamaoncol.2022.3227

This cohort study assesses neutralizing antibody concentrations following a third mRNA-1273 vaccination in immunocompromised patients with hematologic cancers to levels obtained in healthy individuals after the standard 2-dose vaccination schedule.

Research Letter

Handling Informative Premature Treatment or Study Discontinuation for Assessing Between-Group Differences in a Comparative Oncology Trial

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1502-1503. doi:10.1001/jamaoncol.2022.2394

This decision analytical model study examines premature treatment discontinuation in clinical trials for patients with advanced renal cell carcinoma.

Postmarketing Colitis Cases Associated With Alpelisib Use Reported to the US Food and Drug Administration

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1503-1505. doi:10.1001/jamaoncol.2022.3249

This case series investigates reports of 20 patients with colitis temporally associated with alpelisib use.

Association of Sociodemographic Characteristics With Survival Among Patients With Urachal Cancer in California From 1988 to 2019

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1505-1507. doi:10.1001/jamaoncol.2022.3252

This cohort study evaluates the sociodemographic characteristics of patients with urachal cancer, cancer treatments, and the association of patient characteristics with overall survival.

Reporting of Race and Hispanic Ethnicity in Breast Cancer Studies From the National Cancer Database

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1507-1509. doi:10.1001/jamaoncol.2022.3527

This cohort study characterizes the inclusion of Hispanic ethnicity or ethnoracial categories in breast cancer studies from the National Cancer Database.

Review

World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2022;8(10):1493-1501. doi:10.1001/jamaoncol.2022.2844

This narrative review discusses the implications of the 2021 updates to the World Health Organization (WHO) central nervous system (CNS) tumor classification relative to adult-type glioma diagnosis, prognosis, and treatment.

Viewpoint

Race and Ethnicity–Conscious Clinical Research Best Practices

Abstract Full Text
JAMA Oncol. 2022;8(10):1391-1392. doi:10.1001/jamaoncol.2022.2841

This Viewpoint describes the concept of race-conscious medicine in oncology.

Aspirin and the USPSTF—What About Cancer?

Abstract Full Text
JAMA Oncol. 2022;8(10):1392-1394. doi:10.1001/jamaoncol.2022.2967

This Viewpoint discusses the potential misinterpretations in the 2022 US Preventive Services Task Force recommendation statement on the use of aspirin for the prevention of colorectal cancer.

The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers

Abstract Full Text
has multimedia has audio
JAMA Oncol. 2022;8(10):1394-1395. doi:10.1001/jamaoncol.2022.3785

This Viewpoint evaluates factors introduced by the overturn of Roe v Wade that will further complicate the complex, multidisciplinary decision-making involved in treating patients with pregnancy-associated cancer.

Editorial

Reforming Patient Cost Sharing for Cancer Medications in Medicare Part D

Abstract Full Text
JAMA Oncol. 2022;8(10):1398-1400. doi:10.1001/jamaoncol.2022.2828
Invited Commentary

Glutaminase Inhibitors—Do They Have a Role in the Treatment of Metastatic Clear-Cell Renal Cell Carcinoma?

Abstract Full Text
JAMA Oncol. 2022;8(10):1418-1419. doi:10.1001/jamaoncol.2022.3378

Optimizing Histology-Specific Clinical Trials in Soft-Tissue Sarcoma—Are We There Yet?

Abstract Full Text
JAMA Oncol. 2022;8(10):1426-1427. doi:10.1001/jamaoncol.2022.3161
Cancer Care Chronicles

A Lived Experience of Breast Cancer as a Scholar of Intersectionality

Abstract Full Text
JAMA Oncol. 2022;8(10):1396-1397. doi:10.1001/jamaoncol.2022.2838

This essay discusses how a diagnosis of breast cancer changed the author’s perspective on intersectionality, the interpersonal, disciplinary, structural, and especially cultural expectations of persons in marginalized social groups.

Poetry and Oncology

Last Train Home

Abstract Full Text
JAMA Oncol. 2022;8(10):1520. doi:10.1001/jamaoncol.2022.2564
Comment & Response

Underrecognition of Symptoms During Breast Radiotherapy

Abstract Full Text
JAMA Oncol. 2022;8(10):1509-1510. doi:10.1001/jamaoncol.2022.3239

Underrecognition of Symptoms During Breast Radiotherapy

Abstract Full Text
JAMA Oncol. 2022;8(10):1510. doi:10.1001/jamaoncol.2022.3242

Underrecognition of Symptoms During Breast Radiotherapy—Reply

Abstract Full Text
JAMA Oncol. 2022;8(10):1510-1511. doi:10.1001/jamaoncol.2022.3245

Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer

Abstract Full Text
JAMA Oncol. 2022;8(10):1511-1512. doi:10.1001/jamaoncol.2022.3458

Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer

Abstract Full Text
JAMA Oncol. 2022;8(10):1512-1513. doi:10.1001/jamaoncol.2022.3461

Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer

Abstract Full Text
JAMA Oncol. 2022;8(10):1513. doi:10.1001/jamaoncol.2022.3464

Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer—Reply

Abstract Full Text
JAMA Oncol. 2022;8(10):1513-1514. doi:10.1001/jamaoncol.2022.3467

SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1514-1515. doi:10.1001/jamaoncol.2022.3045

SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1515. doi:10.1001/jamaoncol.2022.3048

SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1515-1516. doi:10.1001/jamaoncol.2022.3057

SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US—Reply

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1516-1517. doi:10.1001/jamaoncol.2022.3060

Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials

Abstract Full Text
JAMA Oncol. 2022;8(10):1517. doi:10.1001/jamaoncol.2022.3521

Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply

Abstract Full Text
JAMA Oncol. 2022;8(10):1517-1518. doi:10.1001/jamaoncol.2022.3524
Correction

Error in Figure 2

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1518. doi:10.1001/jamaoncol.2022.3737

Change of Article Status to Open Access

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1518. doi:10.1001/jamaoncol.2022.4054

Errors in Abstract and Affiliations

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1518. doi:10.1001/jamaoncol.2022.4267
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2022;8(10):1379. doi:10.1001/jamaoncol.2021.5521
×